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Abstract
Background: As the World Health Organization grading system for gastroenteropancreatic-neuroendocrine tumors
(GEP-NETs) may not always correlate with tumor progression, it is imperative that other independent predictors of
tumor progression be established. To identify such predictors, we conducted a retrospective histopathological study
of hindgut NETs, obtained from endoscopic procedures, and used statistical analyses to evaluate predictive factors.
Methods: We first obtained clinicopathological data of cases of hindgut NETs. Tissue sections from tumor samples
were prepared and subjected to pathological examination. In particular, we calculated the microvessel density
(MVD) and lymphatic microvessel density (LMVD) values, and performed appropriate statistical analyses.
Results: A total of 42 cases of hindgut NETs were selected for the study, 41 from the rectum and 1 from the
sigmoid colon. Based on the Ki-67 labeling index, 34 cases were classified as NET G1 tumors and 8 as NET G2
tumors. MVD values ranged from 1.4/mm2 to 73.9/mm2 and LMVD values from 0/mm2 to 22.9/mm2. MVD and
LMVD were identified as risk factors for venous and lymphatic invasion of hindgut NETs. Moreover, MVD positively
correlated with the maximum diameter of the tumor.
Conclusions: Tumor progression of NETs may cause angiogenesis and lymphangiogenesis, via an unknown
mechanism, as well as lymphovascular invasion. Angiogenesis likely plays an important role in occurrence and
progression in the initial phase of hindgut NETs.
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Background
Although previous investigators have reported on the
prognostic value of lymphovascular invasion in several
types of neoplasms, the results of these studies are
somewhat controversial with regards to gastroentero-
pancreatic neuroendocrine tumors (GEP-NET) [1–3].
However, a number of recent studies have reported a
higher than expected rate of venous and/or lymphatic
invasion (lymphovascular invasion) in GEP-NET samples
obtained via endoscopic procedures [4–6]. In a case
series from our own institution, we identified a lympho-
vascular invasion rate of approximately 30 % for GEP-
NETs. Therefore, we conducted this study to specifically
evaluate the lymphovascular status of GEP-NETs.
GEP-NETs have traditionally been regarded as rela-
tively rare neoplasms [7]. However, recent surveillance
data have shown the incidence and prevalence of GEP-
NETs to be higher than previously expected, likely due
to recent technical advances in endoscopic and imaging
examinations [8]. In Japan, the rectum is the most fre-
quent site of GEP-NETs [8], as well as the second most
common site in Western countries [4].
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The grading system for GEP-NETs was updated by the
World Health Organization (WHO) in 2010 [9–11]. This
system is based only on the proliferative activity of
tumor cells, as measured by the number of mitotic cells
confirmed per 10 high-power fields (HPFs) and/or by
the percentage of tumor cells showing positive immunore-
activity for the Ki-67 antigen (the Ki-67 labeling index).
However, the proliferative characteristics of tumor cells
may not always predict tumor progression or of its
growth, invasion and metastasis and overall prognosis
[12]. Therefore, it is imperative that other independent
predictors of tumor progression be established.
In Japan, NETs mostly originate in the hindgut, with a
relatively well-established endoscopic procedure used in
most of these cases to remove these hindgut NETs [4,
13]. Previous study [8] has reported an overall preva-
lence of GI-NETs of 6.42 per 100,000 people (95 % con-
fidence interval (CI), 4.50 to 8.34). The specific
prevalence rates of foregut, midgut, and hindgut NETs
were estimated at 1.67 (95 % CI, 0.94–2.40), 0.23 (95 %
CI, 0.18–0.28), and 4.52 (95 %, CI 3.17–5.87) per
100,000 people, respectively. In Japan, hindgut NETs ac-
count for approximately 70 % (70.4 %) of all GI-NETs
(Table 1). Therefore, the aim of our retrospective study
was to perform histopathological and statistical analyses
of hindgut NETs, obtained by endoscopic procedures, to
identify independent predictors of tumor progression
and prognosis, based on pathological findings.
Methods
Identification of hindgut NETs cases for analysis
We searched for cases of hindgut NETs, recorded between
April 1996 and September 2015, using a pathological diag-
nosis support software (‘EXpath’ System, INTEC Inc.,
Tokyo, Japan). The following keywords were used for the
search: ‘carcinoid’, ‘neuroendocrine’, ‘karuchinoid’ (Japanese
for carcinoid), and ‘shinkeinaibunpi’ (Japanese for
neuroendocrine). The terms ‘ohkokettyou, Sjoketyou and
tyokutyou, and S’ (Japanese for transverse colon, sigmoid
colon, and rectum) were used as an additional option to
identify the tumor site. We subsequently retrieved the
formalin-fixed paraffin-embedded (FFPE) tissue sections
of identified hindgut NET cases.
Clinicopathological data of identified hindgut NET cases
We extracted the following clinical data from the medical
records of identified hindgut NET cases for analysis: age,
sex, and outcome. We also extracted reports of patho-
logical findings for review. To conduct the pathological as-
sessment of retrieved specimens, tissue sections from
tumors were prepared and subjected to Hematoxylin and
Eosin (HE) staining for analysis under a light microscope.
Immunohistochemical examinations were performed
using antibodies against the following markers: CD31
(Leica, clone 1A10; 1:20 dilution), chromogranin A
(Roche, clone LK2H10; 1:5 dilution), D2-40 (Roche, clone
D2-40; 1:1 dilution), Ki-67 (Dako, clone MIB-1; 1:50 dilu-
tion), and synaptophysin (Roche, clone MRQ-40; 1:1 dilu-
tion). Tumors were defined as NETs if immunoreactivity
staining was positive for synaptophysin and/or chromo-
granin A. The Ki-67 labeling index was obtained by count-
ing at least 1000 cells in each case, using the Patholoscope
image analysis software (MITANI Corporation, Japan,
URL: http://www.mitani-visual.jp/en/products/bio_imagin-
g_analysis/patholoscope/).
For analysis, microscope images were captured at the
center of the tumor primarily under two magnifications.
Low and High power fields. However, other magnifica-
tions (×100 or ×200) were used for certain cases to pro-
duce multi-panel figures. This was necessary due to the
relatively small number of specimens available for ana-
lysis and the absence of burtons surrounding stromal tis-
sues. A scaling bar was included on all images to explain
length measurements (and these are provided in the
Figure legends). We examined the following additional
pathological data as surrogate measures of tumor pro-
gression: tumor site, maximum tumor diameter, depth of
tumor invasion, surgical margin status, and the status of
lymph node metastasis.
Based on our identification of variation in the density
of vessels and lymphatic vessels during histopathological
examination of our cases, we selected to specifically cal-
culate the microvessel density (MVD) and lymphatic
microvessel density (LMVD) values in tumor specimens.
MVD is defined as the number of blood vessels per unit
area of tumor tissue, while LMVD refers to the number
of lymphatic vessels per unit area. Previous investigators
have reported that MVD may be one of the prognostic
factors of the NETs [14].
To obtain these vessel counts, immunohistopathologi-
cal images of the tumor stained for CD31 (for MVD
Table 1 Epidemiology of gastrointestinal neuroendocrine
tumors in Japan (per 1000,000 population)
2010 (JAPAN)
Overall prevalence of GI-NETs 6.42 (95 % CI 4.50–8.34)
Foregut 1.67 (95 % CI 0.94–2.40)
Midgut 0.23 (95 % CI 0.18–0.28)
Hindgut 4.52 (95 % CI 3.17–5.87)
Incidence of GI-NETs 3.51 (95 % CI 2.50–4.53)
Foregut 1.20 (95 % CI 0.48–1.91)
Midgut 0.15 (95 % CI 0.12–0.18)
Hindgut 2.12 (95 % CI 1.56–2.67)
Legend: The foregut included the esophagus, stomach and duodenum; the
midgut, the jejunum, ileum and vermiform appendix; and the hindgut, the
large intestine and colon
GI-NET, gastrointestinal-neuroendocrine tumor; 95 % CI, 95 %
confidence interval
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Fig. 1 Representative histopathological findings of hindgut neuroendocrine tumors. Legend: a A photomicrograph showing a low-power field of a
hindgut neuroendocrine tumor (NET), with evidence of invasion of the submucosal layer (hematoxylin and eosin (HE) staining; original magnification,
×20; scale bar represents 1000 μm). b A photomicrograph showing a high-power field of a hindgut NET. The tumor cells have a round-to-oval nucleus,
and the nuclear atypia is relatively mild (HE staining; original magnification, ×400; scale bar represents 100 μm). c and d Among the 42 cases in our
study, a positive immunoreactivity for synaptophysin was identified in 42 cases and for chromogranin A in 35 cases (immunohistochemistry,
synaptophysin and chromogranin A; original magnification, ×100; scale bars represent 200 μm)
Fig. 2 Representative images of venous and lymphatic invasion. Legend: a, b To determine the presence or absence of venous invasion, both EVG
staining and immunohistochemistry for CD31 were performed. Venous invasion was confirmed, but no CD31-positive cells were identified. Such difficult
cases were reviewed by more than two expert pathologists (EVG staining and immunohistochemistry for CD31; original magnification, ×200; scale bars
represent 200 μm). c To determine the presence or absence of lymphatic invasion, immunohistochemistry for D2-40 was performed. Difficult cases were
examined by more than two expert pathologists (Immunohistochemistry for D2-40; original magnification × 400; scale bar represents 100 μm)
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count) or D2-40 (for LMVD count) were captured using
a video microscope camera (DS-Fi1, Nikon, Tokyo,
Japan), and the count carried out manually. CD31- and
D2-40-positive structures were defined as vessels if a lu-
minal structure was identified; single cells, positive for
CD31 or D2-40, were not included. MVD and LMVD
were counted in 20 HPFs of histopathological images,
using the hot spot counting method. Counting was facil-
itated by the specificity of CD31 for vascular endothelial
cells, which is higher than when using CD34. For
LMVD, although we recognized the low specific of D2-
40 for lymphatic vessels, we used this staining technique
because of its simplicity and instrumentation, as recog-




Appropriate statistical analyses were performed on the
extracted data. Statistical analyses were performed using
the non-parametric Mann-Whitney U test or Pearson’s
product-moment correlation coefficient, as appropriate
for the data set. Differences were considered significant
at P < 0.05.
Results
Hindgut NETs cases included in the analysis
Forty-seven relevant hindgut NET cases were identified,
with specimens available for retrieval and analysis. Of
these 47 specimens, a tumor lesion was identified in 42
of the collected FFPE tissue sections, with insufficient
Fig. 3 Variation in microvessel density among tumors. Legend: a In
this tumor, there are few CD31-positive endothelial cells and the tumor
has an extremely low microvessel density. No venous invasion was
observable (immunohistochemistry for CD31; original magnification,
×100, scale; bar represents 100 μm). b In this tumor, numerous CD31-
positive endothelial cells were observable and the tumor has a high
microvessel density. This is representative of most of cases with venous
invasion (immunohistochemistry for CD31; original magnification,
×100; scale bar represents 100 μm)
Fig. 4 Differences in microvessel density in tumors with and with without venous invasion. Legend: The microvessel density values of tumors with
venous invasion were significantly higher than for tumors without venous invasion (*, p < 0.001, Mann–Whitney U test; values are expressed as the
mean ± standard deviation)
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tumor tissue available for examination in the remaining
5 cases. The analysis was, therefore, based on the histo-
pathological data of 42 cases of hindgut NETs.
Clinicopathological data of hindgut NET cases
The relevant clinical data were as follows: a mean ± stand-
ard deviation (SD) of age of 59.6 ± 12.0 years (range, 37 to
81 years) and a male-to-female ratio of 23:19. No deaths
from hindgut NETs were reported over the follow-up
period, which ranged between 5 and 191 months. Four pa-
tients with hindgut NET underwent further surgical inter-
vention due to lymphatic invasion detected in the
specimen obtained during the initial endoscopic proced-
ure. In 1 of these 4 patients, lymph node metastasis oc-
curred in a level 1 lymph node. A positive surgical margin
(vertical margin positive) was identified in another case,
the patient refusing additional surgical intervention, but
rather opting for observation and careful follow-up. This
patient maintained a high quality of life over his 36 months
of follow-up, after the endoscopic procedure, with no evi-
dence of recurrent local or distant metastases. Four pa-
tients died of other disease causes, 2 of gastric cancer, 1 of
lung cancer and 1 of cerebral hemorrhage. Overall, among
the 42 cases of NETs, clinical characteristics were available
in the medical record for only 22 patients who underwent
regular medical follow-ups after the endoscopic proced-
ure. With regards to pathological findings, 41 of the 42
cases of hindgut NETs occurred in the rectum and 1 in
the sigmoid colon. The maximum diameter of the tumors
ranged between 998.1 and 10046.0 μm (mean ± SD,
5058.0 ± 2410.3 μm). The depth of tumor invasion was the
submucosal layer in all 42 cases (Figs. 1a and b). On im-
munohistochemical examination, positive immunoreactiv-
ity for synaptophysin was identified in all 42 cases (100 %)
and for chromogranin A was in 35 of 42 (83.3 %) cases
(Fig. 1c and d). The Ki-67 labeling index ranged between
0.1 and 3.2 % (mean ± SD, 1.1 ± 0.8 %). On the basis of the
Ki-67 labeling index, 34 cases were classified as NET G1
tumors and 8 as NET G2 tumors. Venous invasion was
identified in 10 of 42 cases (23.8 %) and lymphatic inva-
sion in 13 of 42 cases (31.0 %; Fig. 2). MVD and LMVD
values varied among tumors (Fig. 3). MVD ranged
between 1.4/mm2 and 73.9/mm2 (mean ± SD, 17.3 ± 14.2/
mm2, Fig. 4) and LMVD from 0/mm2 to 22.9/mm2 (mean
± SD, 6.5 ± 6.5/mm2, Fig. 5). These data are summarized
as Table 1.
Statistical analyses findings
To identify independent predictors of tumor progres-
sion, such as invasion and/or metastasis in hindgut
NETs, we evaluated the predictive valued of MVD
and LMVD. MVD values were higher in tumors with
venous invasion (mean ± SD, 33.8/mm2 ± 20.7/mm2
than in tumors without venous invasion (12.1/mm2 ±
5.3/mm2; p < 0.001, Mann-Whitney U test; Fig. 4).
Moreover, a positive correlation was identified be-
tween MVD and the maximum diameter of the tumor
(r = 0.612, p < 0.001, Pearson’s product-moment correl-
ation coefficient; Table 2). Additionally, LMVD values
were higher in tumors with lymphatic invasion than
in tumors without lymphatic invasion (12.6/mm2 ±
6.9/mm2 versus 3.8/mm2 ± 4.1/mm2); p < 0.001, Mann-
Whitney U test; Fig. 5). No significant correlation was
identified between LMVD and the Ki-67 labeling
index values or the maximum tumor diameter (p =
0.744 and p = 0.136, respectively, Pearson’s product-
moment correlation coefficient; Table 2). Due to the
small number of cases, only univariate analyses of
MVD and LMVD could be performed, and effects of
age, grading, and sex could not be specifically
evaluated.
Discussion
In this study, we specifically calculated the MVD and
LMVD to confirm the presence or absence of lympho-
vascular invasion in hindgut NET cases, and performed
statistical analyses to examine the relationship between
these values and the Ki-67 labeling index and the max-
imum tumor diameter. Morphometric analysis further
revealed MVD and LMVD to be risk factors of venous
and lymphatic invasion in the initial phase of hindgut
NETs. This latter finding results is explained by the
Fig. 5 Differences in lymphatic microvessel density in tumors with and
without lymphatic invasion. Legend: The lymphatic microvessel density
values of tumors with lymphatic invasion were significantly higher than
for tumors without lymphatic invasion (*, p < 0.001, Mann–Whitney U
test; values are expressed as the mean ± standard deviation)
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nature of our samples, with the maximum tumor diam-
eter being <10 mm in most cases.
Our findings provide evidence on the relationship be-
tween tumor progression and angiogenesis. Although it
is widely accepted that the Ki-67 labeling index generally
reflects tumor progression [15, 16], we did not identify a
significant correlation between the Ki-67 labeling index
and the maximum tumor diameter. In contrast, we did
identify a significant positive correlation between MVD
and maximum tumor diameter, indicative of possible
common mechanisms underlying NET progression and
angiogenesis in GEP-NETs. In addition, as venous inva-
sion of NETs is a risk factor of metastasis, this mechan-
ism could influence not only the progression of NETs
but also the spread of distant metastases (especially liver
metastasis). Our analyses revealed a significant positive
correlation between the maximum tumor diameter and
MVD. Previous investigators have also reported that
MVD may be one of the prognostic factors of NETs
[14]. The plausible effect of angiogenesis on tumor pro-
gression is further supported by absence of a correlation
between the LMVD and Ki-67 labeling index values or
the maximum tumor diameter.
Based on this evidence of a plausible effect of angio-
genesis on tumor progression, novel angiogenesis target-
ing agents could prove beneficial in the treatment of
NETs. Future research should include molecular, bio-
logical, and genetic analyses, such as the angiogenesis-
related genes, to more comprehensively identify novel
independent factors of tumor progression, as well as to
inform the development of new, and likely more
effective, treatment strategies.
The limitations of our study need to be considered in
the interpretation of our results. Foremost, this is a retro-
spective case series and, therefore, is subject to the inher-
ent biases of this research design. Moreover, our analysis
was based on only 42 cases of NETs, which prohibited the
use of multivariate analyses to further explore the predict-
ive effects of age, sex, and tumor staging, among other
relevant clinicopathological characteristics.
Despite these limitations, our study provides evidence
of a plausible role of angiogenesis in the occurrence and
progression in the initial phase of hindgut NETs. Our
findings provide a basis for future studies examining the
role of angiogenesis-related genes and of targeted gene
therapies as novel treatments for NETs.
Conclusions
Our study indicated that angiogenesis mechanism play
important roles in occurrence and progression in the ini-
tial phase of hindgut NETs. Furthermore, our data indi-
cated that molecular, biological, and genetic analyses,
such as the examination of angiogenesis-related genes,
might provide efficient and new research strategies to
Table 2 Clinicopathological chracteristics of hindgut
neuroendocrine tumor
Age (years)
Range 37 to 81
mean ± SD 59.6 ± 12.0
MVD (mm2)
Range 1.4 to 73.9






Range 0 to 22.9






Male 23, 54.8 %
Female 19, 45.2 %
Pathological grade (n, %)
NET G1 34, 81 %
NET G2 8, 19 %
Ki 67 labeling index (%)
Range 0.1 to 3.2
mean ± SD 1.1 ± 0.8
Relationship to tumor
diameter
No significant correlation (Pearson’s product–
moment correlation coefficient, p = 0.136)
Venous invasion (n, %)
Negative 32, 76.2 %
Positive 10, 23.8 %
Lymphatic invasion (n, %)
Negative 29, 69 %
Positive 13, 31 %
Tumor diameter (μm)
Range 998.1 to 10046.0
mean ± SD 5058.0 ± 2410.3
Relationship to MVD Significant positive correlation
(Pearson’s product–moment correlation
coefficient, r = 0.612, p < 0.001)
Relationship to LMVD No significant correlation (Pearson’s product–
moment correlation coefficient, p = 0.744)
Pathological stage (n, %)
pStage I 40, 95.2 % (all of them are pT1 and n0)
pStage II 0, 0 %
pStage IIIB 1, 2,4 % (lymph node metasis positive)
Unknown 1, 2.4 % (margin positive)
Legend: In this table clinicopathological characteristics and some statistical
analyses of 42 hindgut neuroendocrine tumors were summarized
MVD microvessel density, LMVD lymphatic microvessel density, SD
standard deviation
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elucidate the progression of NETs as well as identify
novel independent predictors of these tumors.
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